AI drug discovery’s expensive reality
Christina Farr and Ruth Reader
11 min read
Rising compute costs have biotech firms rethinking how they use large language models.
Ruth Reader
Ruth Reader is the Head of Premium Content at Second Opinion.
52 posts
Oura’s IPO Could Become a Watershed Moment for Women’s Health
Christina Farr, Stephanie Davis and Ruth Reader
7 min read
From fertility and menopause to sleep and recovery, Oura is building one of the largest consumer health datasets focused on women.
The Food and Drug Administration in free fall
Christina Farr and Ruth Reader
11 min read
Plus: updates on the Ebola outbreak, CMS' prior authorization program, and Healthcare.gov
AI startups see opportunity in the public sector
Ruth Reader
6 min read
A new class of startups are mining, cleaning, and analyzing data for governments, public health departments, and federally funded clinics.
Healthcare adopts the New Media playbook by hiring in-house journalists
Christina Farr, Dr. William H. Morris and Ruth Reader
11 min read
Plus all the most important news of the week!
Dr. Eric Topol: Medical AI is facing a dangerous 'paradox'
Ruth Reader
5 min read
Health-tech companies doing the right thing are facing an uphill battle
Former FDA Deputy weighs in on the push into ‘real-time clinical trials’
Ruth Reader
7 min read
There’s reason to be excited - even if it seems incremental
AI and the rise of specialty care
Christina Farr and Ruth Reader
9 min read
Ruth here. On Monday, I sat down with the CEO of a health tech company and two health system executives
Scientists want evidence for AI in medicine
Christina Farr and Ruth Reader
4 min read
Patients may not care.
An inside look at Epic’s confidential vendor services agreement
Ruth Reader
8 min read
Startups have for years complained about the difficulty of working with Epic, the electronic health record company with the largest
CMS announces ACCESS participants
Christina Farr and Ruth Reader
6 min read
There's a lot more of them than we expected!